Literature DB >> 18475455

Mechanism of action of 5-arninosalicylic acid.

N A Punchard1, S M Greenfield, R P Thompson.   

Abstract

5-Aminosalicylic Acid (5-ASA) has been used for over 50 years in the treatment of inflammatory bowel disease in the pro-drug form sulphasalazine (SASP). SASP is also used to treat rheumatoid arthritis. However whether the therapeutic properties of SASP are due to the intact molecule, the 5-ASA or sulphapyridine components is unknown. Several mechanisms of action have been proposed for 5-ASA and SASP including interference in the metabolism of arachidonic acid to prostaglandins and leukotrienes, scavenging,of reactive oxygen species, effects on leucocyte function and production of cytokines. However, it is unlikely that the anti-inflammatory properties of SASP and 5-ASA are due to several different properties but more likely that a single property of 5-ASA explains the theraapeutic effects of 5-ASA and SASP. Reactive oxygen species (ROS) are involved in the metabolism of prostaglandins and leukotrienes and can act as second messengers, and so the scavenging of ROS may be the single mechanism of action of 5-ASA that gives rise to its antiinflammatory effects in both inflammatory bowel disease and rheumatoid arthritis.

Entities:  

Year:  1992        PMID: 18475455      PMCID: PMC2365334          DOI: 10.1155/S0962935192000243

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  132 in total

1.  PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION.

Authors:  J E LENNARD-JONES; J J MISIEWICZ; A M CONNELL; J H BARON; F A JONES
Journal:  Lancet       Date:  1965-01-23       Impact factor: 79.321

2.  Distribution and metabolism of salicyl-azo-sulfapyridine. II. A study with S35-salicyl-azo-sulfapyridine and S35-sulfapyridine.

Authors:  A HANNGREN; E HANSSON; N SVARTZ; S ULLBERG
Journal:  Acta Med Scand       Date:  1963-04

3.  Sulphasalazine and salicylazosulphadimidine in ulcerative colitis.

Authors:  J H BARON; A M CONNELL; J E LENNARD-JONES; F A JONES
Journal:  Lancet       Date:  1962-05-26       Impact factor: 79.321

4.  Salicylate other than 5-aminosalicylic acid ineffective in ulcerative colitis.

Authors:  M Campieri; G A Lanfranchi; G Bazzocehi; C Brignola; G Corazza; C Cortini; M Michelini; G Labó
Journal:  Lancet       Date:  1978-11-04       Impact factor: 79.321

5.  The influence of salicyl-azo-sulfapyridine on the immune response to antigenic tumour cells inoculated into the coecal lumen of C3H mice.

Authors:  M L Laursen
Journal:  Scand J Gastroenterol       Date:  1978       Impact factor: 2.423

6.  Sulfasalazine improves psoriasis. A double-blind analysis.

Authors:  A K Gupta; C N Ellis; M T Siegel; E A Duell; C E Griffiths; T A Hamilton; B J Nickoloff; J J Voorhees
Journal:  Arch Dermatol       Date:  1990-04

7.  Determination of prostaglandin synthetase activity in rectal biopsy material and its significance in colonic disease.

Authors:  D W Harris; P R Smith; C H Swan
Journal:  Gut       Date:  1978-10       Impact factor: 23.059

8.  Increased arachidonic acid levels in phospholipids of human colonic mucosa in inflammatory bowel disease.

Authors:  S Pacheco; K Hillier; C Smith
Journal:  Clin Sci (Lond)       Date:  1987-10       Impact factor: 6.124

9.  Antioxidant effects on the prostaglandin endoperoxide synthetase product profile.

Authors:  M P Carpenter
Journal:  Fed Proc       Date:  1981-02

10.  Salicylates used in inflammatory bowel disease and colchicine impair interferon-gamma induced HLA-DR expression.

Authors:  B Crotty; P Hoang; H R Dalton; D P Jewell
Journal:  Gut       Date:  1992-01       Impact factor: 23.059

View more
  13 in total

Review 1.  Postsurgical recurrence of ileal Crohn's disease: an update on risk factors and intervention points to a central role for impaired host-microflora homeostasis.

Authors:  Michael F Cunningham; Neil G Docherty; J Calvin Coffey; John P Burke; P Ronan O'Connell
Journal:  World J Surg       Date:  2010-07       Impact factor: 3.352

Review 2.  Inflammatory bowel disease management. Some thoughts on future drug developments.

Authors:  J Rhodes; G Thomas; B K Evans
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

3.  Epstein-Barr virus is related with 5-aminosalicylic acid, tonsillectomy, and CD19(+) cells in Crohn's disease.

Authors:  Juan C Andreu-Ballester; Rafael Gil-Borrás; Carlos García-Ballesteros; Ignacio Catalán-Serra; Victoria Amigo; Virgina Fernández-Fígares; Carmen Cuéllar
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

4.  Eicosanoid production by the mucosa in inflammatory bowel disease after 5-ASA treatment.

Authors:  F J Zijlstra; A P van Dijk; R J Ouwendijk; I C van Riemsdijk-Overbeeke; J H Wilson
Journal:  Agents Actions       Date:  1993

5.  Therapeutic effects of an azaphenothiazine derivative in mouse experimental colitis.

Authors:  Jolanta Artym; Maja Kocięba; Ewa Zaczyńska; Michał Zimecki; Wojciech Kałas; Leon Strządała; Alicja Pawlak; Małgorzata Jeleń; Beata Morak-Młodawska; Krystian Pluta; Katarzyna Kaleta-Kuratewicz; Jan P Madej; Piotr Kuropka; Jan Kuryszko
Journal:  Histol Histopathol       Date:  2019-12-13       Impact factor: 2.303

6.  Flavonoids and 5-aminosalicylic acid inhibit the formation of neutrophil extracellular traps.

Authors:  Tina Kirchner; Eva Hermann; Sonja Möller; Matthias Klinger; Werner Solbach; Tamás Laskay; Martina Behnen
Journal:  Mediators Inflamm       Date:  2013-12-07       Impact factor: 4.711

Review 7.  The role of microbiome in rheumatoid arthritis treatment.

Authors:  Rahul Bodkhe; Baskar Balakrishnan; Veena Taneja
Journal:  Ther Adv Musculoskelet Dis       Date:  2019-07-30       Impact factor: 5.346

8.  Effect of the combined administration of vitamin-E and 5-aminosalicylic acid on acrylamide-induced testicular toxicity.

Authors:  Nisreen A Rajeh; Dareen Khayyat
Journal:  J Taibah Univ Med Sci       Date:  2017-05-23

9.  CD44 and xCT: The Silver Bullet for Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension?

Authors:  Vineet Agrawal; Anna R Hemnes
Journal:  Am J Respir Cell Mol Biol       Date:  2019-09       Impact factor: 6.914

10.  Engineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut.

Authors:  Pichet Praveschotinunt; Anna M Duraj-Thatte; Ilia Gelfat; Franziska Bahl; David B Chou; Neel S Joshi
Journal:  Nat Commun       Date:  2019-12-06       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.